AR114437A1 - Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos - Google Patents

Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos

Info

Publication number
AR114437A1
AR114437A1 ARP190101131A ARP190101131A AR114437A1 AR 114437 A1 AR114437 A1 AR 114437A1 AR P190101131 A ARP190101131 A AR P190101131A AR P190101131 A ARP190101131 A AR P190101131A AR 114437 A1 AR114437 A1 AR 114437A1
Authority
AR
Argentina
Prior art keywords
conjugates
elimination
disclosure provides
addressing towards
addressing
Prior art date
Application number
ARP190101131A
Other languages
English (en)
Inventor
Lutz Jermutus
Roland Brli
Maria Herva
Damian C Crowther
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of AR114437A1 publication Critical patent/AR114437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En algunas formas de realización, la divulgación provee un conjugado que comprende: a) un péptido que compite con un fragmento Fc de una IgG por la unión a un receptor Fc; y b) una unidad de direccionamiento que direcciona hacia agregados moleculares. En algunas formas de realización, la divulgación provee métodos para usar los conjugados para tratar una enfermedad o trastorno asociado con la formación de agregados.
ARP190101131A 2018-04-30 2019-04-29 Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos AR114437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664345P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
AR114437A1 true AR114437A1 (es) 2020-09-02

Family

ID=66529984

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101131A AR114437A1 (es) 2018-04-30 2019-04-29 Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos

Country Status (12)

Country Link
US (2) US11065336B2 (es)
EP (1) EP3787690A1 (es)
JP (1) JP2021522286A (es)
KR (1) KR20210005097A (es)
CN (1) CN112312927A (es)
AR (1) AR114437A1 (es)
AU (1) AU2019264364B2 (es)
BR (1) BR112020022122A2 (es)
CA (1) CA3098093A1 (es)
MX (1) MX2020011468A (es)
TW (1) TW202014207A (es)
WO (1) WO2019211253A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522286A (ja) * 2018-04-30 2021-08-30 メディミューン リミテッド 凝集体を標的とし、一掃するためのコンジュゲート
MX2023007450A (es) 2020-12-21 2023-10-05 Univ Cornell Sistema de administración de fármacos ligados a péptidos.
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO2009090268A1 (en) 2008-01-17 2009-07-23 Medimmune Limited Peptide mimetics
EP2991677B1 (en) * 2013-05-03 2020-07-15 Yale University Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
JP2021522286A (ja) * 2018-04-30 2021-08-30 メディミューン リミテッド 凝集体を標的とし、一掃するためのコンジュゲート

Also Published As

Publication number Publication date
MX2020011468A (es) 2021-02-09
BR112020022122A2 (pt) 2021-01-26
CN112312927A (zh) 2021-02-02
US20220001016A1 (en) 2022-01-06
WO2019211253A1 (en) 2019-11-07
EP3787690A1 (en) 2021-03-10
AU2019264364B2 (en) 2024-06-06
US11065336B2 (en) 2021-07-20
JP2021522286A (ja) 2021-08-30
US20190328889A1 (en) 2019-10-31
AU2019264364A1 (en) 2020-11-12
CA3098093A1 (en) 2019-11-07
KR20210005097A (ko) 2021-01-13
TW202014207A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
CO2021016552A2 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
AR114437A1 (es) Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
UY38236A (es) COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
PE20210685A1 (es) Anticuerpos que se dirigen al gp120 de vih y metodos de uso
CO2018000809A2 (es) Anticuerpos para cd40
MX2019012811A (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion.
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
CR20170096A (es) Tratamientos conjuntos con anticuerpos anti cd40
PE20230381A1 (es) Proteina de union a rgma
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
EA202190653A1 (ru) Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2021000146A1 (es) Anticuerpos humanizados contra psma

Legal Events

Date Code Title Description
FB Suspension of granting procedure